Publication Reference

Tebbutt NC, Cummins MM, Sourjina T, Strickland AH, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer  2010; 102: 475–481.

Conference Presentation Reference

1. Tebbutt NC, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Gebski V, Munro S, Cummins M; on behalf of the Australasian GI Trials Group. ATTAX: randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5-FU or capecitabine in metastatic oesophago-gastric cancer: final results of an AGITG trial. 43rd Annual Meeting of the American Society of Clinical Oncology; 1–5 Jun 2007; Chicago.
2. Tebbutt N, Gebski V, Strickland A, Gibbs D, Walpole E, Ganju V, Goldstein D, Munro S, Harrod M, Van Hazel G, Australasian Gastro-Intestinal Trials Group. Randomised phase II study evaluating weekly docetaxel in combination with cisplatin and 5FU or capecitabine in metastatic oesophago-gastric cancer. 42nd Annual Meeting of the American Society of Clinical Oncology; 2–6 Jun 2006; Atlanta. Journal Of Clinical Oncology 2006; 24 (18): 194S. 4067.

Aim

This study will help to decide which treatments are most promising and should be compared with current treatments in the future in an effort to improve the time people live after a diagnosis of oesophageal or gastric cancer.

Summary

In Australia and New Zealand, there are approximately 3,485 new cases diagnosed and 2,741 deaths annually from oesophageal and gastric cancers. Therapeutic options for patients with advanced oesophageal and gastric cancer include chemotherapy, but current treatments need to be improved upon. This study is assessing the effectiveness of two different combinations of chemotherapy on the growth of tumours and the undesirable side-effects of the treatments.

Principal Investigator

Doctor Niall Tebbutt, Medical Oncologis, Austin Health VIC

Funding

Sanofi-Aventis Group Pty Limited (Australia)
Roche Products Pty Limited (Australia)